Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 921972

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 921972

Gonorrhea Therapeutics Market - Growth, Trends, and Forecasts (2022 - 2027)

PUBLISHED:
PAGES: 110 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, with the growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives are anticipated to drive market growth.

However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Dual Therapy Segment is Expected to Register Good Growth Over the Forecast Period

By Treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the global market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. WHO recommends dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Also, monotherapy is no longer a viable option in many settings worldwide. In addition, growing public awareness and a large patient pool also contribute to the growth of the gonorrhea therapeutics market.

North America is Estimated to Lead the Gonorrhea Therapeutics Market

North America is expected to lead the market, owing to high standards of healthcare infrastructure and easy availability of sophisticated technology in this region. As per CDC estimates, in 2018 around 583,405 cases of gonorrhea were reported in the United States. However, Europe and the Asia Pacific are followed next after North America owing to the increasing incidence of gonococcal infection, and the rise in collaboration of domestic and international companies in these regions. For instance, In 2019, Binx health announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval, which is expected to drive the gonorrhea therapeutics market in the forecast period.

Competitive Landscape

The market for gonorrhea therapeutics is consolidated in terms of competition with a presence of few major pharmaceutical companies. Some of the major players in the gonorrhea therapeutics market includes Allergan, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Pfizer Inc, Teligent, Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 67485

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Gonorrhea
    • 4.2.2 Growing Government and Private Sector Participation Through National Campaigns
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Social Stigma Associated With Patients Visiting STD Clinics
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Gonococcal Infection
    • 5.1.1 Uncomplicated Gonococcal Infection
    • 5.1.2 Gonococcal Arthritis
    • 5.1.3 Gonococcal Meningitis and Endocarditis
  • 5.2 By Treatment
    • 5.2.1 Monotherapy
    • 5.2.2 Dual Therapy
  • 5.3 By End User
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan, Inc.
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 GlaxoSmithKline plc
    • 6.1.4 Lupin Pharmaceuticals
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Teligent, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!